Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)

NCT01327911 is registered in ClinicalTrials.gov with Neurotech Pharmaceuticals as lead sponsor.

NCT NCT01327911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01327911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)
Lead sponsor
Neurotech Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
September 30, 2016
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic juxtafoveal telangiectasia